Long-Term Weight Maintenance Strategy Our goal is sustainable, long-term improvementnot temporary results
To view a copy of this licence, visit About this article Cite this article Xu, Q., Wang, W., Li, Y
You'll never have to navigate prior authorization alone
Ask your insurer about coverage for other FDA-approved uses of these medications
Reported complications described in some GLP-1 drug claims have included: Severe or persistent gastrointestinal symptoms , such as ongoing nausea, vomiting, or abdominal pain Delayed stomach emptying (gastroparesis) , which has been described by some individuals as involving bloating, nausea, vomiting, or difficulty tolerating food Intestinal complications , including reduced bowel activity (ileus), which may involve abdominal discomfort, cramping, or vomiting Gallbladder-related conditions , such as gallstones or gallbladder inflammation Blood-clot-related conditions , including deep vein thrombosis or pulmonary embolism, described in some reports and legal filings Vision-related problems , including reports involving non-arteritic anterior ischemic optic neuropathy (NAION) discussed in connection with semaglutide in certain contexts Not everyone who takes a GLP-1 medication experiences these issues, and the relationship between GLP-1 drugs and reported complications continues to be evaluated in legal proceedings
TB-500: corneal, dermal and hair-follicle research examining keratinocyte and endothelial migration
